Lexicon (LXRX) Q3 2026 Earnings Call Transcript
Lexicon (LXRX) reported Q3 2026 progress, including completion of patient enrollment in the phase III SONATA-HCM study for HCM, with top-line results expected in Q1 2027. The company also made strides in resubmitting the NDA for ZYNQUISTA in type 1 diabetes, supported by new safety data from the STENO1 study, aiming for resubmission in Q1 2027.
How this was made

The 30-second read
Why it matters
The company’s pipeline updates provide a near‑term catalyst that could move the stock ahead of the Q1 2027 NDA filing.
Market read
Trial enrollment completion and upcoming NDA resubmission are material developments for investors.
What to watch
Potential delays in regulatory review or competition from other SGLT inhibitors.
Background
Lexicon is a clinical‑stage biotech focusing on cardiovascular and metabolic diseases.
Ticker impact
Lexicon reported completion of patient enrollment in its phase III SONATA-HCM study and plans to submit its NDA for ZYNQUISTA in Q1 2027.
potential upside as investors price in upcoming data and regulatory filing.
Enrollment completion reduces clinical risk; NDA resubmission signals near-term catalyst.
Market effects
Advances in HCM and type‑1 diabetes therapies may benefit the broader biotech sector.
Limited to U.S. biotech investors; no immediate regional effect.
Modest, as the news pertains to a niche therapeutic area.
Counterpoint
If trial data later disappoint, the stock could face sharp downside.
Key entities
- CompanyLexicon
Biotech firm developing sotagliflozin (ZYNQUISTA) and other candidates.



